Arkansas Financial Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$436K Hold
1,733
0.06% 79
2026
Q1
$367K Hold
1,733
0.05% 78
2025
Q4
$396K Buy
1,733
+1
+0.1% +$228 0.06% 73
2025
Q3
$401K Buy
1,732
+37
+2% +$7.54K 0.06% 73
2025
Q2
$315K Buy
1,695
+100
+6% +$18.6K 0.05% 69
2025
Q1
$278K Hold
1,595
0.05% 68
2024
Q4
$283K Hold
1,595
0.05% 69
2024
Q3
$315K Sell
1,595
-120
-7% -$22.4K 0.05% 68
2024
Q2
$294K Hold
1,715
0.05% 66
2024
Q1
$312K Hold
1,715
0.06% 62
2023
Q4
$266K Hold
1,715
0.05% 64
2023
Q3
$256K Sell
1,715
-40
-2% -$5.87K 0.05% 62
2023
Q2
$236K Buy
1,755
+211
+14% +$30.9K 0.05% 62
2023
Q1
$246K Hold
1,544
0.05% 58
2022
Q4
$249K Sell
1,544
-140
-8% -$21.5K 0.05% 59
2022
Q3
$226K Buy
1,684
+101
+6% +$14.5K 0.05% 45
2022
Q2
$243K Buy
1,583
+7
+0.4% +$1.07K 0.06% 43
2022
Q1
$255K Hold
1,576
0.05% 44
2021
Q4
$213K Buy
+1,576
New +$186K 0.04% 45

Other funds holding ABBV

Arkansas Financial Group's ABBV Position: Q2 2026 in Review

Arkansas Financial Group held its AbbVie (ABBV) position steady in Q2 2026 at 1,733 shares worth $436K. The position accounts for 0.06% of the portfolio, ranked #79.

Arkansas Financial Group first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Arkansas Financial Group held 1,733 shares of AbbVie worth $436K as of Q2 2026.
  • Arkansas Financial Group left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.06% of Arkansas Financial Group's portfolio in Q2 2026, its #79 holding.
  • Arkansas Financial Group first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Arkansas Financial Group's 13F filing for Q2 2026, filed 20 Jul 2026.